psmA4 Antibody

What is PSMA4 and what cellular functions does it perform?

PSMA4 (proteasome subunit, alpha type, 4) is a critical component of the 20S proteasome core complex involved in protein degradation pathways. It has a calculated molecular weight of 237 amino acids (27 kDa) but typically migrates at approximately 29 kDa on SDS-PAGE gels . The protein is encoded by the PSMA4 gene (Gene ID: 5685) and plays an essential role in the ubiquitin-proteasome pathway, which regulates protein turnover, cell cycle progression, and various cellular signaling events. PSMA4 is widely expressed across multiple tissue types and cell lines, with detection reported in various cancer cell lines including BxPC-3, LNCaP, HeLa, K-562, and U-937 cells . As a constitutive proteasome subunit, PSMA4 is critical for maintaining cellular proteostasis and has been implicated in various pathophysiological conditions.

What applications are PSMA4 antibodies validated for?

PSMA4 antibodies have been extensively validated for multiple research applications with specific performance parameters:

Both antibody types have demonstrated effectiveness across these applications, though with different optimal dilution ranges reflecting their distinct binding properties . The monoclonal antibody typically requires much higher dilutions for Western blot applications, indicating its potentially higher affinity or specificity in this context.

What is the species reactivity profile of available PSMA4 antibodies?

PSMA4 antibodies exhibit cross-reactivity with orthologous proteins from multiple species due to the high evolutionary conservation of proteasome subunits:

The broader reactivity profile of the monoclonal antibody makes it particularly valuable for comparative studies across species . When conducting cross-species research, it is advisable to verify reactivity by running parallel samples from different species to confirm consistent detection patterns.

What are the optimal sample preparation protocols for PSMA4 detection?

For optimal PSMA4 detection, sample preparation protocols should be tailored to specific experimental applications:

For Western blot analysis:

• Extract total protein using RIPA buffer supplemented with protease inhibitors

• Denature samples at 95°C for 5 minutes in reducing loading buffer

• Load 20-40 μg of total protein per lane for cell lysates

• Include positive control samples from validated cell lines (e.g., BxPC-3, HeLa, K-562)

For immunohistochemistry:

• Recommended antigen retrieval: TE buffer pH 9.0

• Alternative method: citrate buffer pH 6.0

• Optimal section thickness: 4-6 μm

• Validated positive controls include human pancreas cancer tissue and mouse liver tissue

For immunofluorescence:

• Fixation with 4% paraformaldehyde for 15 minutes

• Permeabilization with 0.1% Triton X-100

• Blocking with 5% BSA

• HeLa cells serve as reliable positive controls

How should antibody dilutions be optimized for different PSMA4 experimental systems?

Antibody dilution optimization is critical for maximizing signal-to-noise ratio and ensuring reproducible results:

• Begin with a broad range pilot experiment using manufacturer's recommended dilutions (e.g., 1:1000-1:4000 for WB with polyclonal antibody)

• Conduct a systematic titration series at 2-3 fold increments (e.g., 1:1000, 1:2000, 1:4000)

• Evaluate signal intensity, background levels, and specific band pattern for each dilution

• Select optimal dilution that provides maximum specific signal with minimal background

• Verify reproducibility across at least three independent experiments

• For quantitative applications, ensure the selected dilution falls within the linear detection range

It is essential to note that optimal dilutions may vary significantly between the polyclonal (11943-2-AP) and monoclonal (68203-1-Ig) antibodies, with the latter typically requiring much higher dilutions (1:5000-1:50000) for Western blot applications .

What strategies should be employed to validate PSMA4 antibody specificity?

Comprehensive antibody validation is essential for generating reliable research data:

• Molecular weight verification: Confirm detection at the expected molecular weight (29 kDa)

• Positive control samples: Include validated cell lines (BxPC-3, LNCaP, HeLa, K-562)

• Recombinant protein controls: Use purified PSMA4 protein as a positive control

• Knockdown/knockout validation:

  • Perform siRNA-mediated knockdown of PSMA4

  • Use CRISPR/Cas9-engineered knockout cell lines

  • Compare antibody signal between wildtype and depleted samples

• Orthogonal antibody comparison: Compare detection patterns using both polyclonal and monoclonal antibodies targeting different epitopes

• Cross-reactivity assessment: Test against similar proteasome subunits to confirm specificity

• Mass spectrometry validation: Confirm identity of immunoprecipitated proteins

This multi-layered validation approach ensures confidence in antibody specificity and experimental results.

How do post-translational modifications affect PSMA4 detection?

PSMA4 undergoes various post-translational modifications (PTMs) that can impact antibody recognition:

• Phosphorylation: PSMA4 contains multiple potential phosphorylation sites that may influence antibody binding

• Ubiquitination: As part of the proteasome complex, PSMA4 may interact with ubiquitinated proteins or become modified itself

• Detection considerations:

  • The observed molecular weight (29 kDa) is slightly higher than calculated (27 kDa), suggesting PTMs

  • Use phosphatase treatment to determine if phosphorylation contributes to mobility shifts

  • Consider native vs. denaturing conditions when analyzing proteasome complexes

  • When investigating specific PTMs, use appropriate modification-specific antibodies in conjunction with general PSMA4 detection

Researchers should be aware that certain experimental conditions or disease states may alter the PTM profile of PSMA4, potentially affecting antibody recognition patterns.

What are common causes of non-specific binding with PSMA4 antibodies and how can they be mitigated?

Non-specific binding can compromise experimental results and should be systematically addressed:

• Insufficient blocking:

  • Extend blocking time to 1-2 hours

  • Try alternative blocking agents (5% BSA, 5% non-fat milk, commercial blockers)

  • For tissue sections, include additional blocking steps for endogenous peroxidase or biotin

• Suboptimal antibody dilution:

  • Increase dilution factor, particularly for the monoclonal antibody (68203-1-Ig) which may require dilutions up to 1:50000 for Western blot

  • Perform systematic titration experiments

• Cross-reactivity with related proteasome subunits:

  • Run parallel blots with multiple antibodies targeting different proteasome subunits

  • Verify band separation patterns on higher-resolution gels

  • Consider 2D electrophoresis for complex samples

• Sample-specific interference:

  • Pre-absorb antibody with cell/tissue lysates from negative control samples

  • Use purified IgG fractions rather than serum

  • Include detergents (0.1% Tween-20) in wash buffers

• Detection system issues:

  • Switch detection methods (HRP vs. fluorescent)

  • Optimize incubation time with secondary antibodies

  • Use species-specific secondary antibodies with minimal cross-reactivity

How can PSMA4 antibodies be effectively used in multiplex immunofluorescence experiments?

Multiplex detection protocols require careful optimization for successful co-localization studies:

• Antibody compatibility assessment:

  • Ensure primary antibodies are raised in different host species

  • If using multiple rabbit antibodies, consider sequential detection with direct labeling

  • Validate each antibody individually before combining

• Fluorophore selection:

  • Choose fluorophores with minimal spectral overlap

  • Account for relative abundance of different targets when selecting brightness

  • Consider photobleaching properties for imaging sequence

• Optimized protocol for PSMA4 multiplex detection:

  • Fix HeLa cells with 4% paraformaldehyde (15 minutes)

  • Permeabilize with 0.1% Triton X-100 (10 minutes)

  • Block with 5% BSA (1 hour)

  • Incubate with PSMA4 antibody at validated dilution (1:50-1:500 for polyclonal, 1:200-1:800 for monoclonal)

  • Use fluorophore-conjugated secondary antibodies with minimal cross-reactivity

  • Include DAPI nuclear counterstain

  • Mount with anti-fade medium to preserve signal

• Controls for multiplex experiments:

  • Single-antibody controls to assess bleed-through

  • Secondary-only controls to assess non-specific binding

  • Biological positive and negative controls

  • Peptide competition controls to verify specificity

What are the relative advantages of polyclonal versus monoclonal PSMA4 antibodies?

The choice between polyclonal (11943-2-AP) and monoclonal (68203-1-Ig) PSMA4 antibodies should be guided by specific experimental requirements:

Researchers should consider these factors when selecting the appropriate antibody for their specific application . For quantitative studies requiring high reproducibility, the monoclonal antibody may offer advantages, while the polyclonal antibody might provide superior sensitivity for detecting low-abundance targets.

How does the performance of PSMA4 antibodies compare in different cancer cell lines?

Performance analysis across multiple cancer cell lines reveals important considerations for experimental design:

• Western blot detection patterns:

  • Strong signal in BxPC-3 (pancreatic cancer), LNCaP (prostate cancer), HeLa (cervical cancer), K-562 (leukemia), and U-937 (lymphoma) cells

  • Consistent detection at 29 kDa across all positive cell lines

  • Expression levels may vary by cell type, requiring optimization of loading amounts

• Immunohistochemistry performance:

  • Robust detection in human pancreatic cancer tissue

  • Differential staining intensity may reflect biological variations in PSMA4 expression

  • Antigen retrieval conditions significantly impact staining quality (TE buffer pH 9.0 recommended)

• Immunofluorescence patterns:

  • Primarily nuclear and cytoplasmic distribution in HeLa cells

  • Pattern reflects known localization of proteasome complexes

  • Co-staining with other proteasome subunits yields high colocalization

When comparing across cell lines, researchers should normalize loading based on total protein rather than housekeeping genes, as proteasome components may affect expression of common loading controls.

What are the critical considerations for PSMA4 co-immunoprecipitation experiments?

Co-immunoprecipitation (Co-IP) of PSMA4 requires specific protocol adaptations:

• Lysis buffer selection:

  • Use gentle lysis buffers to preserve protein-protein interactions

  • Recommended: 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, protease inhibitors

  • Avoid harsh detergents like SDS that disrupt proteasome complexes

• Antibody amount optimization:

  • Use 0.5-4.0 μg of PSMA4 antibody 11943-2-AP per 1.0-3.0 mg of total protein lysate

  • Pre-clear lysates with protein A/G beads to reduce non-specific binding

  • Include IgG control IP to identify non-specific interactions

• Bead selection and binding conditions:

  • For rabbit polyclonal (11943-2-AP): Protein A or Protein A/G beads

  • For mouse monoclonal (68203-1-Ig): Protein G beads

  • Incubation: 4 hours to overnight at 4°C with gentle rotation

• Washing stringency balance:

  • Use progressively higher salt concentrations if background is high

  • Typical wash buffer: 50 mM Tris-HCl pH 7.5, 150-300 mM NaCl, 0.1% NP-40

  • Perform 4-5 washes to minimize non-specific binding

• Detection of interacting partners:

  • Probe for known proteasome components to validate successful IP

  • Consider mass spectrometry for unbiased identification of interactors

  • Verify novel interactions with reciprocal IP experiments

Validated cell lines for PSMA4 IP include BxPC-3 cells, which have demonstrated successful immunoprecipitation with the 11943-2-AP antibody .

How should PSMA4 antibodies be incorporated into studies of proteasome inhibitor effects?

PSMA4 antibodies can provide valuable insights in proteasome inhibitor research:

• Experimental design considerations:

  • Include time-course analysis (0-48 hours of inhibitor treatment)

  • Use dose-response experiments with multiple inhibitor concentrations

  • Compare different classes of proteasome inhibitors (e.g., bortezomib, carfilzomib, ixazomib)

• Key readouts to monitor:

  • PSMA4 protein levels by Western blot

  • PSMA4 subcellular localization by immunofluorescence

  • Co-immunoprecipitation of PSMA4 with other proteasome subunits

  • Post-translational modifications of PSMA4

• Recommended controls:

  • Vehicle-only treated samples

  • Non-proteasome targeting compounds as negative controls

  • Positive controls with established proteasome inhibitors

  • Analysis of ubiquitinated protein accumulation to confirm inhibition

• Protocol adaptations:

  • For Western blot: Include ubiquitin blotting to verify inhibitor efficacy

  • For IF/ICC: Examine changes in nuclear vs. cytoplasmic distribution

  • For IHC: Compare treated vs. untreated tissue samples

This methodological approach enables researchers to distinguish between direct effects on PSMA4 and secondary consequences of proteasome inhibition.

What emerging applications are being developed for PSMA4 antibodies in cancer research?

PSMA4 antibodies are finding new applications in cancer research beyond traditional protein detection:

• Prognostic biomarker development:

  • Quantitative analysis of PSMA4 expression in tumor samples

  • Correlation with clinical outcomes and treatment response

  • Development of standardized IHC scoring systems

• Therapeutic target assessment:

  • Evaluation of PSMA4 as a potential cancer vulnerability

  • Antibody-drug conjugate approaches targeting proteasome components

  • Combination strategies with existing proteasome inhibitors

• Proteasome dynamics visualization:

  • Live-cell imaging using fluorescently-tagged antibody fragments

  • Super-resolution microscopy of proteasome complexes

  • Analysis of proteasome redistribution during cellular stress

• Single-cell analysis platforms:

  • Integration with mass cytometry (CyTOF) for multiparameter analysis

  • Single-cell proteomics applications

  • Spatial transcriptomics combined with protein localization

These emerging applications highlight the continued importance of well-validated PSMA4 antibodies in advancing our understanding of proteasome biology in cancer.

How can researchers effectively combine PSMA4 antibodies with multi-omics approaches?

Integration of PSMA4 antibody-based detection with multi-omics technologies enables comprehensive systems biology insights:

• Proteogenomic integration:

  • Correlate PSMA4 protein levels with gene expression data

  • Analyze effects of genetic alterations on protein abundance

  • Identify potential regulatory mechanisms controlling PSMA4 expression

• Phosphoproteomics combinations:

  • Use PSMA4 IP followed by phosphopeptide enrichment

  • Map phosphorylation sites on PSMA4 and interacting partners

  • Correlate phosphorylation status with proteasome activity

• Interactome analysis:

  • Perform PSMA4 antibody-based proximity labeling (BioID, APEX)

  • Compare interactome changes under different cellular conditions

  • Validate key interactions with co-IP and microscopy

• Spatial multi-omics:

  • Combine PSMA4 immunofluorescence with in situ sequencing

  • Analyze spatial distribution of proteasome components in tissue context

  • Correlate with local transcriptome and metabolome data